International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate
- PMID: 40545966
- DOI: 10.1097/PAS.0000000000002430
International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate
Abstract
Working Group 1 at ISUP's Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal proliferation (AIP), atypical adenomatous hyperplasia (AAH)/adenosis, and proliferative inflammatory atrophy (PIA). Objectives were to compile recent evidence, interrogate current practices, and vote on recommendations, with 67% approval defined as consensus. Consensus was reached against the reporting of the low-grade form of PIN. HGPIN need not be reported when concomitant cancer or atypical small acinar proliferation suspicious for cancer exists adjacent to it, for biopsy or prostatectomy specimens. Finally, while the clinical significance of unifocal HGPIN in biopsies remains uncertain, there is stronger evidence for multifocal isolated HGPIN as a predictor of subsequent cancer detection. By consensus, multifocal HGPIN should continue being reported. Slight refinement was achieved regarding IDC criteria. The consensus opinion was that a dense cribriform to solid proliferation need not demonstrate marked nuclear atypia/ pleomorphism to qualify as IDC. The inverse scenario of marked atypia without dense cribriform/solid proliferation fell just short (65%) of consensus for IDC. Redesignating cribriform HGPIN as AIP achieved consensus. AIP found alone or with grade group 1 cancer warrants an explanatory comment. However, agreement was not attained to report AIP in the presence of invasive cancer, in either needle biopsy or prostatectomy. Finally, the optional reporting of PIA or AAH/adenosis in biopsies as pertinent negatives both fell short of consensus. This guidance should help pathologists standardize reporting, staying focused on the clinically actionable aspects of these lesions.
Keywords: atypical intraductal proliferation; consensus conference; intraductal carcinoma; precursor lesion; prostate; prostatic intraepithelial neoplasia.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest and Source of Funding: N.A.'s institution has received research funding from Arnivas, Astellas, AstraZeneca, Bayer, Bristol Meyers Squibb, CRISPR Therapeutics, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Merck, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, and Seattle Genetics. For the remaining authors none were declared.
References
-
- McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986;17:64–71.
-
- Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer. 1987;59:788–794.
-
- Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology. 2012;60:4–27.
-
- Iczkowski KA, Torkko KC, Wilson RS, et al. Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. Hum Pathol. 2014;45:54–58.
-
- Drago JR, Mostofi FK, Lee F. Introductory remarks and workshop summary. Urology. 1989;suppl. 34:2.
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
